ASCO 2026.3.4 Living Guideline: Lorlatinib Takes Priority in First-Line ALK-Positive NSCLC After Landmark Seven-Year CROWN Results
2026 Prix Galien Awards Recognize Major Advances in Cancer Treatment, Screening and Immunotherapy
FASCO 2027: Recognizing Dedication to Oncology
Re-Irradiation in Pediatric CNS Tumors: Balancing a Second Chance of Cure Against Long-Term Toxicity
Carla Ferrell and Sista Strut 2026: Breast Cancer Awareness Mission
Can the Tumor’s Own B Cells Reveal the Next Immunotherapy Target?
Top Gastroesophageal Cancer Updates From ESMO 2026
Adding SPICE to SBRT: Intentional Hotspots Associated with Improved Local Control in Early-Stage NSCLC
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
